Adial Pharmaceuticals Applies For FDA Priority Voucher Program For AD04

Adial Pharmaceuticals submitted its AD04 application for consideration under the FDA Commissioner’s National Priority Voucher Pilot Program. The announcement is a regulatory milestone for the company, but it does not indicate approval or provide financial terms. Market impact is likely limited unless the application is accepted or advanced.

Analysis

Adial Pharmaceuticals submitted its AD04 application for consideration under the FDA Commissioner’s National Priority Voucher Pilot Program. The announcement is a regulatory milestone for the company, but it does not indicate approval or provide financial terms. Market impact is likely limited unless the application is accepted or advanced.